GlassScriptPhysician profile
Joshua Douglas Nellis
NPI 1134890288
$3,511.88
in general payments reported to CMS, 2019-2025
22 companies · $537 in 2025
The $537 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $940 · 2023: $1,417 · 2024: $618 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,473 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,472.92 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $519.13 | 2022-2023 | Farxiga |
| Boston Scientific Corporation | $485.82 | 2022-2024 | Watchman Flx, Resonate El Icd Vr, Watchman Access System |
| Medtronic, INC. | $380.88 | 2022-2025 | Micra, Linq II |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.27 | 2022-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $260.28 | 2022-2025 | |
| Alnylam Pharmaceuticals INC. | $207.90 | 2023-2025 | Amvuttra, Onpattro |
| Merck Sharp & Dohme LLC | $185.87 | 2022-2025 | Verquvo, Capvaxive |
| Edwards Lifesciences Corporation | $184.95 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $182.65 | 2023-2025 | Camzyos |
| Amgen INC. | $166.56 | 2022-2025 | Repatha, Repatha |
| Regeneron Healthcare Solutions, INC. | $138.48 | 2023-2024 | Evkeeza |
| Esperion Therapeutics, INC. | $119.36 | 2022 | |
| Pfizer INC. | $93.94 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $76.14 | 2022-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $47.84 | 2022-2023 | Lifevest |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $47.14 | 2022-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $43.38 | 2022-2024 | Uptravi |
| Lexicon Pharmaceuticals, INC. | $29.77 | 2023-2024 | Inpefa |
| Atricure, INC. | $26.92 | 2025 | Epi-Ease Epicardial Access System |
| Genzyme Corporation | $18.87 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $18.33 | 2023 | Arcalyst |
| Scpharmaceuticals INC. | $14.40 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Nellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.